Krzysztof Gawronski

Dr. Krzysztof Gawronski

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2007 in Blood
Verified
Journal Article
Closed access
PDF file
Ewa RobakEwa Robak
Ewa Robak
KJKrzysztof Jamroziak
Krzysztof Jamroziak
JGJoanna Gora-Tybor
Joanna Gora-Tybor
JBJerzy Z Blonski
Jerzy Z Blonski
MKMarek Kasznicki
Marek Kasznicki
LKLech Konopka
Lech Konopka
Cladribine (2-chlorodeoxyadenosine, 2-CdA) treatment-associated infections may shorten potentially long-term survival in hairy cell leukemia (HCL). In search of the optimal mode of 2-CdA administration, 132 patients with untreated HCL were randomized to receive either standard 5-day 2-CdA protocol or a novel schedule of 6 weekly 2-CdA infusions suggested to be less toxic. Analysis of treatment response confirmed similar complete remission rates, overall response rates, progression-free survival, and overall survival in both 2-CdA protocols. However, we did not observe lower toxicity in the weekly schedule. Of special interest, no significant differences were found in the rate of grade 3/4 infections (18% for daily and 26% for weekly protocol, difference −8.2%; 95% confidence interval [CI] −23.2% to 6.9%; P = .28) and the rate of septic deaths (3% for daily and 2% for weekly protocol, difference 1.4%; 95% CI −4.3% to 7.0%; P = .64). In conclusion, HCL treatment with weekly 2-CdA infusions is equally effective but no safer than the standard 5-day 2-CdA protocol.

1 February 2010 in International Journal of Infectious Diseases
Verified
Journal Article
Closed access
ELEwa Lech-Marańda
Ewa Lech-Marańda
MSMarek Seweryn
Marek Seweryn
SGSebastian Giebel
Sebastian Giebel
JHJerzy Holowiecki
Jerzy Holowiecki
BPBeata Piatkowska-Jakubas
Beata Piatkowska-Jakubas
Ewa RobakEwa Robak
Ewa Robak

1 October 2011 in Transplantation Proceedings
Verified
Journal Article
Closed access
AWA. Waśko-Grabowska
A. Waśko-Grabowska
PRP. Rzepecki
P. Rzepecki
SOS. Oborska
S. Oborska
JBJ. Barzał
J. Barzał
KGKrzysztof Gawronski
Krzysztof Gawronski
CSCezary Szczylik
Cezary Szczylik

31 October 2011 in Transplantation Proceedings
Verified
Journal Article
Closed access
WPW. Pielichowski
W. Pielichowski
JBJ. Barzal
J. Barzal
KGKrzysztof Gawronski
Krzysztof Gawronski
BMB. Mlot
B. Mlot
SOS. Oborska
S. Oborska
PRP. Rzepecki
P. Rzepecki

26 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Iwona KwiecieńIwona Kwiecień
Iwona Kwiecień
ERElżbieta Rutkowska
Elżbieta Rutkowska
KGKrzysztof Gawronski
Krzysztof Gawronski
KKKatarzyna Kulik
Katarzyna Kulik
ADAlicja Dudzik
Alicja Dudzik
PRPiotr Rzepecki
Piotr Rzepecki
Myelodysplastic syndromes (MDS) are common malignant disorders with a poor prognosis. It is necessary to search for new rapid diagnostic methods to detect MDS patients with cytogenetic changes. The aim of the study was to assess new hematological neutrophil- and monocyte- related parameters I then bone marrow of MDS patient with and without cytogenetic changes. A total of 45 patients with MDS, including 17 patients with cytogenetic changes, were examined. The study was conducted using the Sysmex XN-Series hematological analyzer. New neutrophil and monocyte parameters, such as immature granulocytes (IG), neutrophil reactivity intensity (NEUT-RI), neutrophil granularity intensity (NEUT-GI), neutrophil size (NE-FSC) and neutrophil/monocyte data relating to granularity, activity and volume (NE-WX/MO-WX, NE-WY/MO-WY, NE-WZ/MO-WZ, MO-X, MO-Y, MO-Z) were evaluated. We observed higher median proportions of NE-WX, NE-WY, NE-WZ, and IG counts in MDS patients with cytogenetic changes than in patients without cytogenetic changes. The NE-FSC parameter was lower in MDS patients with cytogenetic changes than in patients without cytogenetic changes. The combination of new neutrophil parameters was found to be a new successful approach in distinguishing MDS patients with cytogenetic changes from patients without cytogenetic changes. It appears that there may be unique neutrophil parameter signatures associated with an underlying mutation.

1 January 2018 in Polish Archives of Internal Medicine
Verified
Journal Article
Open access
MDMonika Długosz-Danecka
Monika Długosz-Danecka
WJWojciech Jurczak
Wojciech Jurczak
EŁEwa Łątka-Cabała
Ewa Łątka-Cabała
MMMarta Morawska
Marta Morawska
KGKrzysztof Gawronski
Krzysztof Gawronski
IHIwona Hus
Iwona Hus
INTRODUCTION Fludarabine-or bendamustine-based upfront immunochemotherapy is the current standard of care in fit patients with chronic lymphocytic leukemia (CLL). These regimens are poorly tolerated by patients with comorbidities, for whom the obinutuzumab-chlorambucil combination became the recommended first-line treatment. OBJECTIVES We aimed to analyze real-life experience with the obinutuzumab-chlorambucil combination as the frontline treatment in elderly and unfit patients. PATIENTS AND METHODS The retrospective analysis included 86 elderly patients (median age, 74 years) with CLL and a significant burden of comorbidities, treated with obinutuzumab-chlorambucil as the frontline regimen. All patients had a Cumulative Illness Rating Scale score greater than 6 and/or creatinine clearance of 30 to 69 ml/min. RESULTS Overall response rate at 2 months after treatment completion was 95.3%, with complete remission (CR) rate of 43% and partial remission (PR) rate of 52.3%. Stable disease rate was 4.7%. Progressive disease was not observed after treatment completion. The median progression-free survival (PFS) was not reached after a median follow-up of 18 months; estimated PFS at 30 months was 62%. We observed 6 relapses (7%), 3 (3.5%) in patients obtaining CR, and 3 (3.5%) in those with PR after immunochemotherapy. The most frequent adverse events were neutropenia and infusion-related reactions (IRRs). Grade-3 neutropenia occurred in 11.6% of patients, and grade-3 IRRs, in 2.3%. There were no adverse events of grade 4 or 5. CONCLUSIONS Our data confirm that the obinutuzumab-chlorambucil combination is an effective and well-tolerated regimen in untreated CLL patients with comorbidities.